Table 3.

Safety outcomes for patients in the propensity-score matched cohort by groups (SGLT-2 inhibitors/non-SGLT-2 inhibitors).

Safety Outcome	SGLT-2 Inhibitors (n = 38)	Non-SGLT-2 Inhibitors (n = 38)	p-Value
Discontinuation of SGLT-2 inhibitors	1 (3%)	–	–
Discontinuation of other GLDs	10 (26%)	10 (26%)	1
Worsening renal function	1 (2.6%)	2 (5.3%)	0.94
Death from renal cause	0	0	1
Hospitalization for renal cause	0	2 (5.3%)	0.16
Hospitalization for hepatic injury, metabolic acidosis, ketoacidosis, or diabetic ketoacidosis.	0	0	1

GLD: glucose-lowering drugs; SGLT-2: sodium-glucose cotransporter-2; “–“: not applicable.